Successful use of long-term follow-up in patients with chronic myeloid leukemia with a deep molecular response at reduced doses of 2nd generation tyrosine kinase inhibitors: clinical cases and literature review

Successful use of long-term follow-up in patients with chronic myeloid leukemia with a deep molecular response at reduced doses of 2nd generation tyrosine kinase inhibitors: clinical cases and literature review

Therapy with tyrosine kinase inhibitors (TKI) allows to achieve a deep molecular response in 6070% of patients with chronic myeloid leukemia (CML). According to the current guidelines CML patients receive a long-term treatment with TKI in standard dose. The frequently observed adverse effects (AE) o...

Full description

Bibliographic Details
Main Authors: M. A. Gurianova, E. Yu. Chelysheva, O. A. Shukhov, A. G. Turkina
Format: Article
Language:Russian
Published: "Consilium Medicum" Publishing house 2020-09-01
Series:Терапевтический архив
Subjects:
chronic myeloid leukemia
tyrosine kinase inhibitors
major molecular response
deep molecular response
adverse effects
doses reduction
imatinib
nilotinib
dasatinib
Online Access:https://ter-arkhiv.ru/0040-3660/article/viewFile/43131/pdf

Internet

https://ter-arkhiv.ru/0040-3660/article/viewFile/43131/pdf

Similar Items